IMV
vs
S
S&P TSX Composite Index (Canada)
IMV
Over the past 12 months, IMV has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +28% growth.
Stocks Performance
IMV vs S&P TSX Composite Index (Canada)
Performance Gap
IMV vs S&P TSX Composite Index (Canada)
Performance By Year
IMV vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IMV Inc
Glance View
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
